Comparative behavioral and neurochemical studies of R- and S-1-methyl-1,2,3,4-tetrahydroisoquinoline stereoisomers in the rat.
Journal Title: Pharmacological Reports - Year 2012, Vol 64, Issue 4
Abstract
Background: 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTIQ) is present in human and mammalian brain as a racemate (R,S) of two stereoisomers: R- and S-1MeTIQ. The racemate is a mixture of the endogenous, synthesized in the brain dextrorotary R-1MeTIQ, and the exogenous, levorotary form, S-1MeTIQ. Methods: In this study, we compared the effect of these two stereoisomers of 1MeTIQ with the racemate in the context of their influence on dopamine metabolism and in vivo dopamine release in the rat striatum. Additionally, a behavioral study was used to examine the influence of both enantiomers R- and S-1MeTIQ on locomotor activity of rats. Results: The behavioral studies showed that both R- and S-1MeTIQ enantiomers, like the racemate, produced biphasic effects: a slight decrease in the exploratory locomotor activity, and then an increase in the basal locomotor activity. Biochemical ex vivo experiments showed that S-1MeTIQ produced a much stronger inhibition of MAO-dependent dopamine oxidation than the racemate. R-1MeTIQ, in opposite to S-isoform and racemate, did not block dopamine oxidation in the structures which contain dopamine nerve endings (striatum, nucleus accumbens), and in fact did not suppress the level of its intraneuronal metabolite, DOPAC in these brain regions. However , an in vivo microdialysis study demonstrated that the racemate and both stereoisomers (R-1MeTIQ to a lesser extent) significantly elevated the concentration of dopamine in the extraneuronal space in the rat striatum. What is more, the concentration of an extraneuronal dopamine metabolite 3-methoxytyramine (3-MT), which is an indicator of its release, was considerably increased by all the compounds. Conclusions: In summary of the results, it can be stated that S-1MeTIQ, like the racemate and in contrast to R-stereoisomer, inhibits MAO-dependent dopamine oxidation in all investigated brain structures. In addition, both these substances potentiated COMT-dependent O-methylation in the brain, however, also R-1MeTIQ produced such effect but to a lesser extent. In conclusion, we suggest that R- and S-1MeTIQ enantiomers like the racemate may demonstrate neuroprotective properties in the brain via the activation of dopamine O-methylation catabolic pathway and elevation of its methylated product - 3-MT.
Authors and Affiliations
Agnieszka Wąsik, Irena Romańska, Jerzy Michaluk, Lucyna Antkiewicz-Michaluk
Keywords
Related Articles
- EP ID EP114439
- DOI -
- Views 66
- Downloads 0
Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3.
Background: We have previously shown that due to its cytotoxic and cytostatic activities, valproic acid (VPA), but not levetiracetam (LEV), may have potential as a drug for treating human ovarian cancer. In the present s...
Differential effects of glycine on the anticonvulsant activity of D-cycloserine and L-701,324 in mice.
The anticonvulsant effects of D-cycloserine, which is a partial agonist of the glycine/N-methyl-D-aspartate (NMDA) receptor, and L-701,324, which is a selective and potent antagonist that acts at the glycine site, were s...
Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients.
KYNA, an antagonist of ionotropic glutamate receptors and alpha7 nicotinic receptors, has been found as well in the brain as in the periphery. The altered metabolism of KYNA, especially its deficiency, can lead to the en...
Application of magnetic resonance diffusion anisotropy imaging for the assessment neuroprotecting effects of MPEP, a selective mGluR5 antagonist, on the rat spinal cord injury in vivo.
Magnetic resonance diffusion anisotropy imaging (DAI) of the rat spinal cord after contusion using weight-drop method was used to study the neuroprotecting effect of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5...
Inhibitors of type 2 sodium glucose co-transporters - a new strategy for diabetes treatment.
In the last few years, the type 2 sodium glucose co-transporters (SGLT2) have been the subject of particular attention as a new, potent group of anti-diabetic drugs. SGLT2 inhibitors block glucose reabsorption in the kid...